Emisphere Technologies launches oral Eligen B12 tablets

Emisphere Technologies, a biopharmaceutical company, has launched its first commercially available product, oral Eligen B12.

According to Emisphere Technologies, oral Eligen B12 (100mcg) has been specifically developed to help improve vitamin B12 absorption and bioavailability with a patented formulation.

Life Extension will have certain exclusivity in the US for distribution via the internet and also at specialty health food and nutritional retail outlets including; The Vitamin Shoppe, GNC and Vitamin World. Oral Eligen B12 (100mcg) tablets will be available starting November 2009. Financial terms of the agreement were not disclosed.

Emisphere is also reportedly working on a high dose medical food Eligen B12 product (1000mcg) to compete directly with the standard high dose B12 injection currently administered to millions of individuals under medical supervision for B12 deficiency.

Michael Novinski, president and CEO of Emisphere Technologies, said: "We are very excited that our first product introduction will help to advance the field of nutrition by offering a superior oral formulation to improve vitamin B12 absorption and bioavailability.

"By partnering with Life Extension, a highly respected company in the nutrient and supplement field, we are confident that we will have the proper marketing and sales infrastructure to allow oral Eligen B12 (100mcg) to be successful."

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Related terms: ceo, food, health, marketing, medical, nutrition, president, retail, sales, technology